4.7 Article

Rapamycin Protects against Neuron Death in In Vitro and In Vivo Models of Parkinson's Disease

Journal

JOURNAL OF NEUROSCIENCE
Volume 30, Issue 3, Pages 1166-1175

Publisher

SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.3944-09.2010

Keywords

-

Categories

Funding

  1. Department of Defense [DAMD 17-03-1, W81XWH-08-1-0465, W81XWH-08-1-0522]
  2. National Institutes of Health/National Institute of Neurological Disorders and Stroke [AG21617, NS062180, NS064191, NS11766, NS38370, NS042269]
  3. Parkinson's Disease Foundation
  4. Thomas Hartman Foundation, Muscular Dystrophy Association/Wings Over Wall Street
  5. American Parkinson's Disease Foundation

Ask authors/readers for more resources

We report that rapamycin, an allosteric inhibitor of certain but not all actions of the key cellular kinase mammalian target of rapamycin ( mTOR), protects neurons from death in both cellular and animal toxin models of Parkinson's disease (PD). This protective action appears to be attributable to blocked translation of RTP801/REDD1/Ddit4, a protein that is induced in cell and animal models of PD and in affected neurons of PD patients and that causes neuron death by leading to dephosphorylation of the survival kinase Akt. In support of this mechanism, in PD models, rapamycin spares phosphorylation of Akt at a site critical for maintenance of its survival-promoting activity. The capacity of rapamycin to provide neuroprotection in PD models appears to arise from its selective suppression of some but not all actions of mTOR, as indicated by the contrasting finding that Torin1, a full catalytic mTOR inhibitor, is not protective and induces Akt dephosphorylation and neuron death.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available